Rhumbline Advisers Has $2.96 Million Stock Holdings in Certara, Inc. (NASDAQ:CERT)

Rhumbline Advisers grew its position in shares of Certara, Inc. (NASDAQ:CERT) by 4.0% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 277,452 shares of the company’s stock after buying an additional 10,739 shares during the period. Rhumbline Advisers owned approximately 0.17% of Certara worth $2,955,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Blue Trust Inc. increased its position in shares of Certara by 112.3% in the third quarter. Blue Trust Inc. now owns 3,925 shares of the company’s stock worth $46,000 after purchasing an additional 2,076 shares during the period. Harbor Capital Advisors Inc. grew its stake in Certara by 18.4% during the third quarter. Harbor Capital Advisors Inc. now owns 20,144 shares of the company’s stock worth $236,000 after buying an additional 3,136 shares in the last quarter. Atria Investments Inc increased its holdings in Certara by 21.6% in the 3rd quarter. Atria Investments Inc now owns 19,743 shares of the company’s stock valued at $231,000 after buying an additional 3,501 shares during the period. TimesSquare Capital Management LLC raised its position in shares of Certara by 3.1% in the 3rd quarter. TimesSquare Capital Management LLC now owns 956,655 shares of the company’s stock valued at $11,202,000 after buying an additional 29,090 shares in the last quarter. Finally, Versor Investments LP acquired a new position in shares of Certara in the 3rd quarter valued at approximately $162,000. Institutional investors and hedge funds own 73.96% of the company’s stock.

Wall Street Analysts Forecast Growth

CERT has been the topic of a number of research analyst reports. William Blair reaffirmed a “market perform” rating on shares of Certara in a report on Thursday. Barclays lifted their target price on Certara from $12.00 to $13.00 and gave the company an “equal weight” rating in a research report on Friday. Robert W. Baird lowered their target price on Certara from $18.00 to $13.00 and set a “neutral” rating for the company in a research note on Tuesday, November 5th. TD Cowen initiated coverage on shares of Certara in a research note on Thursday. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Stephens reiterated an “overweight” rating and set a $17.00 price objective on shares of Certara in a research report on Thursday. Four analysts have rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat.com, Certara has an average rating of “Moderate Buy” and an average price target of $15.83.

Certara Stock Performance

Shares of CERT opened at $11.98 on Friday. Certara, Inc. has a 1 year low of $9.41 and a 1 year high of $19.87. The company has a debt-to-equity ratio of 0.28, a current ratio of 2.86 and a quick ratio of 2.86. The stock’s fifty day moving average price is $12.45 and its two-hundred day moving average price is $11.63. The firm has a market cap of $1.93 billion, a PE ratio of -59.90, a PEG ratio of 9.29 and a beta of 1.57.

About Certara

Certara, Inc, together with its subsidiaries, provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access in the United States and internationally. It offers solutions for model-informed drug development, as well as biosimulation solution used to predict both pharmacokinetics and pharmacodynamics.